Trial Profile
A Phase II Trial Of ZD1839 (Iressa) In Metastatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 05 May 2011 Status changed from active, no longer recruiting to completed.
- 19 Jul 2007 Status change
- 04 Jun 2007 Status changed from suspended to in progress.